M. Smet

发表

A Dual PPAR α/γ Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects

Haiyuan Zhu, K. Decochez, B. Keymeulen, 2006 .

Idarucizumab, a Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Elderly and Renally Impaired Subjects

S. Glund, S. Norris, P. Reilly, 2014 .

Endocrine consequences of long-term intrathecal administration of opioids.

J. van Buyten, R. Abs, T. Van Havenbergh, 2000, The Journal of clinical endocrinology and metabolism.

Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers

S. Glund, S. Ramael, P. Reilly, 2013 .

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

V. Cocquyt, D. Panebianco, P. Nygren, 2005, Cancer Chemotherapy and Pharmacology.

and pharmacokinetic effects of m r subtype selective agonist, compared to lorazepam and placebo in healthy volunteers

J. Gerven, M. Pieters, A. Cohen, 2014 .

Taranabant, a Novel Cannabinoid-1 Receptor Inverse Agonist, Increases Energy Expenditure in Overweight and Moderately Obese Subjects

S. Heymsfield, J. Wagner, K. Gottesdiener, 2007 .

Effect of Rofecoxib on the Pharmacokinetics of Digoxin in Healthy Volunteers

B. Gertz, R. Lins, J. Schwartz, 2001, Journal of clinical pharmacology.

Effect of Sitagliptin on the Pharmacokinetics of Simvastatin

G. Herman, A. Bergman, B. Keymeulen, 2009, Journal of clinical pharmacology.

Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers

S. Glund, S. Imazu, S. Ramael, 2016, Thrombosis and Haemostasis.

Lack of Effect of Aprepitant on Digoxin Pharmacokinetics in Healthy Subjects

M. Goldberg, M. Feuring, M. Wehling, 2003 .

Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring

L. V. Van Gaal, C. D. De Block, K. Bervoets, 2005, Diabetes Care.

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

M. Decramer, J. Schellens, J. Schellens, 2001, European journal of cancer.

Influence of the selective cyclooxygenase-2 inhibitor, MK-0966 [MK], on digoxin [DG] serum concentrations

B. Gertz, R. Lins, J. Schwartz, 1998 .

Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects

J. Wagner, K. Lasseter, S. Ramael, 2008, Clinical pharmacology and therapeutics.

Multiple‐Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

D. Bloomfield, L. Bortel, O. Laterza, 2008, Clinical pharmacology and therapeutics.

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

J. Gerven, A. Cohen, M. Murphy, 2007 .

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.

J. Gerven, R. Schoemaker, Z. Diamant, 2008, Pulmonary pharmacology & therapeutics.